HepaTx

About the offering

HepaTx Corporation is a pre-clinical stage regenerative medicine company based in Palo Alto, CA, founded on breakthrough technology licensed from Stanford University. The company is developing next-generation cell therapies for liver regeneration, with its lead product Hx-001 targeting severe liver diseases including MASH, autoimmune hepatitis, alcoholic hepatitis, and acute-on-chronic liver failure as an alternative to liver transplants. The core technology involves taking a small sample of fat tissue, reprogramming it into hepatocyte-like cells, and re-injecting those cells into patients to naturally rebuild and heal damaged liver tissue. HepaTx has a collaboration and license agreement with the Mayo Clinic, with an IND filing planned for 2027 and a Phase I clinical trial targeted for 2027/2028. The company has raised $2.4M from venture funds including $500k from Greysky Venture Partners, raised over $2M at Y Combinator Demo Day (including $150k from YC directly), and received $700k in grant funding. Notable backers include Y Combinator, Asymmetry Ventures, Stanford StartX Fund, Checkmate Capital Group, and iSELECT Fund. The founding team is led by CEO Eric Schuur, PhD, who has 25+ years of life science leadership across gene therapy, diagnostics, and oncology, and Chief Business Officer Claudia Preziosi, who oversees fundraising, partnerships, and operations. The company's proprietary platform is designed to enhance cell therapy potency, scalability, and economic viability, with plans to expand beyond Hx-001 to additional product iterations (Hx-002, Hx-003) and its ProteoTrack Technology. HepaTx is addressing a market where over 30 million Americans suffer from liver disease, more than 1 million develop end-stage liver failure annually, and only 1 in 10 receive a life-saving transplant, with the procedure costing up to $1.25M and carrying a 15–35% rejection risk within the first 90 days.

FAQ